We initially conducted a multicenter, randomized trial (n ¼ 43), and subsequently a questionnaire study (n ¼ 209) of participating hospitals, to evaluate whether infused fresh frozen plasma (FFP) could prevent the occurrence of hepatic veno-occlusive disease (VOD) after stem cell transplantation (SCT). Forty-three patients were divided into two groups: 23 receiving FFP infusions and 20 not receiving it. VOD developed in three patients not receiving FFP. Plasma von Willebrand factor (VWF) antigen levels were lower at days 0, 7 and 28 after SCT in patients receiving FFP than in those not receiving it, whereas plasma ADAMTS13 activity (ADAMTS13:AC) did not differ between them. Plasma VWF multimer (VWFM) was demonstrated to be defective in the highBintermediate VWFM during the early post-SCT phase, but there was a significant increase in high VWFM just before VOD onset. This suggests that a relative enzyme-tosubstrate (ADAMTS13/high-VWFM) imbalance is involved in the pathogenesis of VOD. To strengthen this hypothesis, the incidence of VOD was apparently lower in patients receiving FFP infusions than in those not receiving it (0/23 vs 3/20) in the randomized trial. Further, the results combined with the subsequent questionnaire study (0/36 vs 11/173) clearly showed the incidence to be statistically significant (0/59 vs 14/193, P ¼ 0.033).
Introduction
Hepatic veno-occlusive disease (VOD) is a life-threatening complication that develops in 1-54% of patients undergoing allogenic stem cell transplantation (SCT). [1] [2] [3] [4] [5] [6] Hepatic VOD is clinically characterized by hyperbilirubinemia, painful hepatomegaly and fluid retention. 2, 3 Histologically, hepatic VOD is marked by fibrosis of sinusoids, necrosis of pericentral hepatocytes and narrowing of central veins with eventual fibrosis. 7 Recent work suggests that the primary site of toxic injury caused by chemotherapy and/or radiation before SCT is the sinusoidal endothelial cells and that this initial insult is followed by a series of biologic processes that ultimately leads to circulatory compromise of centrilobular hepatocytes, fibrosis and obstruction of liver blood flow. 7 However, the precise pathogenesis of hepatic VOD has yet to be clarified.
von Willebrand factor (VWF) is synthesized in vascular endothelial cells and released into the plasma as 'unusually large' VWF multimers (UL-VWFM), which actively interact with platelets. 8, 9 In the normal circulation, UL-VWFM are rapidly degraded into smaller VWFM by ADAMTS13 (a disintegrin-like metalloproteinase with thrombospondin type-1 motifs 13), 10, 11 which cleaves the Tyr842-Met843 bond within the VWF A2 domain. 12, 13 Deficiency of ADAMTS13 caused either by mutations of the ADAMTS13 gene 10 or by inhibitory autoantibodies against ADAMTS13 14, 15 increases plasma levels of UL-VWFM, which leads to platelet clumping and/or thrombi under high shear stress, resulting in thrombotic thrombocytopenic purpura (TTP). 16 We previously demonstrated that plasma ADAMTS13 activity (ADAMTS13:AC) is reduced in hepatic VOD patients after SCT compared to non-VOD patients, even before conditioning therapy, 17 and that its activity could, therefore, be a predictor for the development of hepatic VOD. Additionally, ADAMTS13:AC is significantly low in patients with advanced liver cirrhosis 18 and those with alcoholic hepatitis. 19 Furthermore, we have demonstrated a rapid decrease in ADAMTS13:AC in association with early adverse events including ischemia-reperfusion injury and/ or acute graft rejection in living donor-related liver transplantation. 20 Our most recent study demonstrates that ADAMTS13 is produced exclusively in hepatic stellate cells (HSCs) located in the space of Disse adjacent to endothelial cells. 21 Considering that hepatic sinusoidal endothelial cell injury is an important causative factor in the development of hepatic VOD 1 and that ADAMTS13:AC is reduced in hepatic VOD, 17 it is of particular interest to evaluate the effect of fresh frozen plasma (FFP) administration as a supplemental source of ADAMTS13 in patients at high risk for post-SCT hepatic VOD.
In this study, we performed a multicenter, prospective, randomized controlled trial, and a subsequent study of participating hospitals by questionnaires to evaluate whether or not the infusion of FFP could prevent the occurrence of hepatic VOD in high-risk patients who had undergone SCT. Towards elucidating the mechanism that underlies the development of VOD, we sequentially determined plasma levels of ADAMTS13:AC, and its substrates, VWF antigen (VWF:AG) and UL-VWFM in a randomized controlled trial.
Materials and methods

Study design
The study on prevention of hepatic VOD associated with SCT was conducted at 10 hospitals in Osaka, Hyogo and Nara prefecture. The study was performed between April 2001 and March 2003, and was a multicenter, randomized and controlled study. A subsequent study was carried out between January 2004 and December 2006 by questionnaires sent to participating hospitals. With respect to the randomized controlled trial, patients were eligible to participate in this prospective study if they were at high risk for developing VOD after allogenic SCT and fulfilled one of the following criteria: (1) intensified conditioning regimen, (2) second SCT, (3) liver dysfunction and (4) receiving intensified chemotherapy until just before SCT because of the poor situation of the underlying disease. Physicians from the referring hospitals registered patients to our registration office by facsimile, with patient information including age, gender and underlying disease. Patients were divided into a child group (18-year-old or under) and an adult group (over 18-year-old). Patients in each group were then randomly divided into two groups: patients to receive FFP infusion (FFP ( þ ) group) and those not to receive it (FFP (À) group). FFP was infused twice a week during the conditioning regimen and until day 28 after SCT in patients in the FFP ( þ ) group. The volume of FFP infused was based upon body weight and determined as follows: 1 unit ( ¼ 80 ml) for patients under 10 kg, 2 units for 10-20 kg, 3 units for 20-30 kg, 4 units for 30-40 kg and 5 units for over 40 kg. The amount of FFP infused on this protocol was calculated to contribute about a 10% increase in plasma ADAMTS13:AC, which was enough to eliminate UL-VWFM in patients with congenital TTP, termed Upshaw-Schulman syndrome. 22, 23 In our previous study, plasma ADAMTS13:AC was about 20% of the normal control level between pre-conditioning and day 21 in patients with hepatic VOD. 17 We therefore attempted to maintain plasma ADAMTS13:AC at the level of 30% of normal control throughout the study, by FFP infusion. As the half-life of plasma ADAMTS13:AC has been reported to be approximately 3 days, 24 we decided to infuse FFP twice weekly.
A diagnosis of hepatic VOD was made according to the criteria of McDonald et al.;
2 VOD patients needed to have at least two of the following clinical features within day 30 after transplantation: (1) jaundice, (2) hepatomegaly and right upper quadrant pain and (3) ascites and/or unexplained body weight gain. Citrated plasma was obtained from patients before the conditioning regimen (pre-SCT) and on days 0, 7, 14, 21 and 28 (post-SCT), and was stored in aliquots at À801C until use. ADAMTS13:AC, VWF:AG, and UL-VWFM levels were determined using these plasma samples. ADAMTS13 inhibitor was analyzed using plasma from day 28. Other laboratory parameters, including thrombin-antithrombin complex (TAT), D-dimer, thrombomodulin (TM), tissue plasminogen activator/ plasminogen activator inhibitor-1 (t-PA/PAI-1) complex and antithrombin (AT), were measured at pre-SCT and on days 0, 7, 14, 21 and 28. The study protocol was approved by the ethics committee of each participating hospital. All patients gave written informed consent before registration in the study.
The subsequent questionnaire was sent to 10 participating hospitals asking whether or not prophylactic FFP infusion to prevent hepatic VOD had been given in highrisk patients who had undergone SCT, and requesting information on the incidence of hepatic VOD in these patients with and without FFP infusion. Measurements ADAMTS13:AC was assayed using a highly sensitive, novel enzyme-linked immunsorbent assay (ELISA), recently developed by our laboratory. 25 The normal level of ADAMTS13:AC using this assay in 55 healthy individuals was 99.1721.5% (mean7s.d.). 25 The ADAMTS13 inhibitor was evaluated using heat-inactivated plasma at 561C for 30 min. 14, 15 One Bethesda unit of inhibitor was defined as the amount of plasma that reduces ADAMTS13:AC to 50% of the control, 26 and its titer was estimated to be significant in more than 0.5 Bethesda U/ml. The UL-VWFM was evaluated by SDS-0.9% agarose electrophoresis followed by western blotting with luminographic detection. 27, 28 Multimers were defined as low molecular 29 Furthermore, the bands corresponding to higher molecular weight, which could never be detected in pooled normal plasma, were defined as UL-VWFM. VWF:AG was measured by a sandwich ELISA using a rabbit anti-human VWF polyclonal antibody (DakoCytomation, Kyoto, Japan). The value obtained from normal individuals (n ¼ 20, 13 males and 7 females aged 20-40 years) was 102733%. 9 
Statistical analysis
All experimental data are presented as means7s.d. Paired and unpaired comparisons between the two groups were performed using the Student's t-test and Fisher exact test. A two-tailed P-value of less than 0.05 was considered statistically significant. Analyses were carried out using the statistical software Statview (version 5.0, SAS Institute, Cary, NC, USA).
Results
Randomized control study Patient characteristics. Of 47 patients enrolled, 15 patients belonged to the child group and 32 belonged to the adult group. Of these, a patient belonging to the FFP ( þ ) group and three patients belonging to the FFP (À) group were excluded from this protocol, because they could not undergo SCT because of poor physical condition. Finally, 43 patients consisting of 15 in the child group and 28 in the adult group were investigated. Twenty-three patients were assigned to the FFP ( þ ) group and the remaining 20 patients to the FFP (À) group. There were no statistically significant differences between the two groups with regard to clinical features and laboratory findings. The clinical characteristics and transplant procedures in patients finally enrolled are shown in Table 1 .
Clinical features of VOD patients with respect to VWF:AG, ADAMTS13:AC and VWF multimers. Case no. 8 with hepatic VOD was a 53-year-old female diagnosed with leukemic transformation of myelodysplastic syndrome who received a mini-transplant from a human leukocyte antigen (HLA)-matched sibling while she had active disease (Table 1) . At day 14 after SCT, this patient developed hyperbilirubinemia (5.1 mg/dl), weight gain and right upper quadrant pain, and was thus diagnosed as having hepatic VOD ( Figure 1a ). She was treated with steroids from day 14 and FFP since day 28, and she completely recovered at day 40 after SCT. In this case, VWF multimers corresponding to high and intermediate molecular weight, which are usually seen in normal plasma, were lacking pre-SCT before conditioning (Figure 1b) . VWF multimers gradually appeared from day 0 to day 7 after SCT. VWF:AG increased from 64% (pre-SCT) to 396% (day 7), and ADAMTS13:AC decreased from 67% (pre-SCT) to 30% (day 7), resulting in an increasing ratio of VWF:AG to ADAMTS13:AC from 1.0 (pre-SCT) to 13.0 (day 7). A week later, VWF:AG decreased to 171%, but ADAMT-S13:AC further decreased to 24%, resulting in ratios of VWF:AG to ADAMTS13:AC as high as 7.1 at day 14, when hepatic VOD developed (Figures 1a and b ). Thereafter, ADAMTS13:AC increased and VWF:AG remained relatively unchanged. This patient completely recovered by day 40, after the occurrence of hepatic VOD.
Case no. 12 was a 53-year-old male who received a bone marrow transplant from an HLA-matched unrelated donor for refractory acute lymphocytic leukemia (Table 1) . At day 28 after SCT, this patient exhibited mild jaundice (1.3 mg/ dl), weight gain and painful hepatomegaly, and was then diagnosed as having hepatic VOD (Figure 1c) . He was treated with FFP infusions from day 35, but unfortunately died of hepatic failure due to VOD on day 40 after SCT. In this case, VWF multimer patterns were similar to those in case no. 8: VWF multimers of high and intermediate molecular weight were lacking at day 0 (just after SCT), but gradually appeared between days 7 and 21 ( Figure 1d ). VWF:AG gradually increased from 101% (day 0) to 205% (day 21), and ADAMTS13:AC gradually decreased from 51% (day 0) to 43% (day 21), resulting in increasingly high ratios of 2.0 (day 0) to 4.8 (day 21). A week later, VWF:AG further increased and reached 234%, and ADAMTS13:AC decreased to 32%, resulting in a high ratio of VWF:AG to ADAMTS13:AC of 7.3 at day 28, when hepatic VOD developed (Figures 1c and d) .
Case no. 14 was a 41-year-old female with active acute myelocytic leukemia who underwent BMT from an HLAmatched unrelated donor. Soon after SCT, she exhibited weight gain and painful hepatomegaly, and was diagnosed as having hepatic VOD on day 7. This patient was therefore dropped from the study and treated with FFP infusions. She completely recovered from hepatic VOD at day 42 after SCT, and was categorized as a VOD case in the FFP (À) group.
Comparison of plasma VWF:AG, ADAMTS13:AC and VWF multimers between patients receiving and not receiving FFP infusions. We next evaluated the effect of FFP on the clinical parameters of ADAMTS13:AC and VWF:AG in patients receiving and not receiving FFP infusions. There were no differences in TAT, D-dimer, TM, PAI-I and AT III between FFP (À) and ( þ ) groups (Table 2) . VWF:AG gradually increased over the time period pre-SCT to day 28 post-SCT in patients belonging to the FFP (À) group (Figure 2 ). In contrast, in patients belonging to the FFP ( þ ) group, the VWF:AG did not increase at days 0 and 7, but gradually increased thereafter between days 14 and 21, and later decreased at day 28. There was a significant difference in VWF:AG at days 0, 7 and 28 between the groups receiving and not receiving FFP (day 0: 96739 vs 147778, Po0.05; day 7: 103762 vs 156783, Po0.05; and day 28: 146782 vs 212781, Po0.05) (Figure 2 ). On the other hand, ADAMTS13:AC gradually decreased from pre-SCT to day 28 in both groups. No difference in the levels of ADAMTS13:AC was observed between the groups. The ratio of VWF:AG to ADAMTS13:AC gradually increased from pre-SCT to day 14 in patients in the FFP (À) group, but in patients in the FFP ( þ ) group, this ratio did not increase at days 0 and 7 but gradually increased later at day 14 ( Figure 2 ). Plasma inhibitor of ADAMTS13 at day 28 was detected only in one patient overall (patient no. 26), who belonged to the FFP ( þ ) group and exhibited an inhibitor level of 1.3 Bethesda U/ml.
We further investigated VWF multimer patterns in patients from the FFP (À) and ( þ ) groups because VWF multimers of high and intermediate molecular weight were specifically lacking pre-SCT in case 8 and at day 0 post-SCT in case 12, but thereafter gradually increased in these cases (Figures 1b and d) . Representative VWF multimer patterns are shown in Figure 3 . In patients from the FFP (À) group, VWF multimers corresponding to high and/or intermediate molecular weight were less or absent at pre-SCT and on days 0 and 7 in case 1 ( Figure 3a) ; at pre-SCT and on days 0, 14 and 21 in case 5 ( Figure 3b) ; and at pre-SCT and on days 0, 7 and 21 in case 10 ( Figure 3c ). In contrast, in patients from the FFP ( þ ) group, no apparent changes in VWF multimer patterns were found throughout SCT, including during the preconditioning period when they compared them to VWF multimer levels found in normal control plasma.
The incidence of hepatic VOD occurrence by randomized controlled trial. Out of the 20 patients belonging to the FFP (À) group, three (15%) patients (patient no. 8, 12 and 14) developed hepatic VOD. In contrast, none of the 23 patients in the FFP ( þ ) group did so (Table 3 ). The incidence of VOD was clearly higher in the FFP (À) group than in the FFP ( þ ) group, but the difference between the FFP (À) group and ( þ ) group did not reach statistical significance (P ¼ 0.092) because of the small number of patients in the study. As for risk factors for the development of hepatic VOD, all three patients with VOD came from the 29 patients who had been treated with intensified chemotherapy until just before SCT. Both case 8 and 12 came from the 11 patients with liver dysfunction, and case 14 was one of 21 patients who received an intensified conditioning regimen. There was thus no relationship between these risk factors for developing hepatic VOD. Further, we compared ADAMT-S13:AC and VWF:AG among four criteria of risk factors as described in Materials and methods. However, no significant difference was found in either ADAMTS13:AC and VWF:AG among these criteria (data not shown).
The incidence of VOD occurrence by subsequent questionnaire study According to the questionnaire, two out of 10 participating hospitals gave prophylactic FFP infusions to prevent hepatic VOD in high-risk patients who had undergone SCT, but others did not. Hepatic VOD developed in 11 of 173 high-risk patients who did not receive prophylactic FFP infusions (Table 3 ). In contrast, hepatic VOD never occurred in 36 high-risk patients who had prophylactic FFP infusion. Based on the result under this questionnaire, the difference in the incidence of hepatic VOD did not reach statistical significance between patients receiving and not receiving prophylactic FFP infusions (P ¼ 0.120). However, when we analyzed all the patients who underwent SCT between 2001 and 2006, the incidence of hepatic VOD was significantly lower in patients receiving prophylactic FFP infusions (0/59) than in those who did not (14/193) (0 vs 7.3%, P ¼ 0.033) ( Table 3) .
Discussion
In this study, we performed a randomized controlled trial, and a subsequent study by questionnaire, to evaluate whether prophylactic FFP infusions could prevent the occurrence of hepatic VOD in high-risk patients receiving SCT. As for the incidence of hepatic VOD in the randomized controlled study, 3 (15%) of 20 patients belonging to the FFP (À) group developed hepatic VOD, whereas none of the 23 patients belonging to the FFP ( þ ) group did so. The incidence between patients receiving and not receiving FFP did not reach statistical significance because of the small numbers of enrolled patients. However, when analysis involving all the patients examined both the randomized controlled trial and the subsequent study by questionnaire, the incidence of hepatic VOD was significantly lower in patients receiving prophylactic FFP infusion than in those not doing so (Table 3) . These results suggest that prophylactic FFP infusions may be instrumental in preventing the development of hepatic VOD after SCT.
In the patients who developed VOD (cases 8 and 12) in the randomized controlled study, VWF:AG progressively increased and ADAMTS13:AC gradually decreased, resulting in ratios of 13.0 at day 7 in case 8, and 4.8 at day 21 in case 12, which were notably higher than that found in normal subjects (1.0). Hepatic VOD developed a week later, when the ratio of VWF:AG to ADAMTS13:AC showed values as high as 7.1 in case 8, and 7.3 in case 12. An inverse correlation between decreased ADAMTS13:AC and increased VWF:AG was thus seen in our VOD patients. These findings were consistent with previous 21, 29, 38) , no apparent changes in VWF multimer patterns were found throughout SCT including the preconditioning period, when compared to patterns found in normal control plasma (d, e, f). The multimers over the dotted line indicate unusually large VWF multimers (UL-VWFM), which can never be detected in normal plasma.
findings in pathological conditions including liver cirrhosis, chronic renal insufficiency, acute inflammatory states and major surgery. 18 Furthermore, our previous study 17 demonstrated that the mean value of ADAMTS13:AC pre-SCT was 32% in seven patients with hepatic VOD. In this study, ADAMTS13:AC was, however, 67 and 55% pre-SCT in cases 8 and 2, respectively. The activity thereafter decreased from 67 to 24% on day 14 in case 8, and from 55 to 32% on day 28 in case 12. From these results, there appeared to be a possibility that hepatic VOD could develop even in the patient whose plasma ADAMTS13:AC pre-SCT did not drop below 30%, indicating that the imbalance of VWF:AG to ADAMTS13:AC before and throughout SCT may be more important for the development of hepatic VOD than the decrease of ADAMT-S13:AC.
Surprisingly, VWF multimers corresponding to high and intermediate molecular weight, which are usually seen in normal plasma, were absent before SCT in case 8 and on day 0 in case 12 (Figures 1b and d) , but thereafter gradually appeared. These results suggest that the initial absence of high and intermediate VWF multimers at preconditioning or just after SCT, and subsequent appearance of these VWF multimers in combination with the increase in VWF:AG and decrease in ADAMTS13:AC may play an important role in the development of VOD after SCT. It remains unclear why high and intermediate VWF multimers were lacking at preconditioning and/or during the early period after SCT but thereafter gradually appeared in VOD patients. We speculate, however, that the target lesion caused by intensive chemotherapy and/or total body irradiation given in the setting of SCT is to the sinusoidal endothelial cells. Indeed, chemotherapy including cyclophosphamide and busulfan before SCT is a regimen associated with a high incidence of hepatic VOD, 4 and total body irradiation causes radiation-induced liver disease. 30 The amount of VWF released from injured endothelial cells may be increased at first, but may decrease thereafter because the endothelial cells are extensively damaged. After SCT, as damaged endothelial cell gradually regenerate, the release of VWF may increase, resulting in the appearance of high and intermediate VWF multimers. Under these circumstances, plasma ADAMTS13 may be consumed to degrade the large amounts of VWF derived from damaged hepatic endothelial cells. Moreover, ADAMTS13 that is exclusively generated in the HSCs may be decreased owing to the liver injury itself. Our previous report that plasma ADAMTS13:AC is significantly reduced in patients with hepatic VOD even before and throughout SCT 17 supports the hypothesis that ADAMTS13:AC decreases may be an indicator of impending development of VOD. This imbalance of decreased activity of ADAMTS13 vs increased production of VWF:AG before and during the early stage after SCT would contribute to a microcirculatory disturbance that could ultimately lead to VOD, especially in zone 3 of the hepatic lobule where hepatocytes are easily damaged by hypoxia. 1 Whether or not patients develop VOD after SCT may depend upon the degree of imbalance between VWF:AG and ADAMTS13:AC at preconditioning and/or just after SCT.
We then compared clinical parameters between patients receiving and not receiving FFP infusions to evaluate the effect of FFP on the prevention of VOD. VWF:AG was significantly lower at days 0, 7 and 28 in patients receiving FFP than in those not doing so. The reciprocal relationship between gradually decreased ADAMTS13:AC and gradually increased VWF:AG after SCT was seen in the FFP (À) group, but not in the FFP ( þ ) group (Figures 2a and b) . No difference in the levels of ADAMTS13:AC was found between the two groups ( Figure 2b ). The ratio of VWF:AG to ADAMT-S13:AC tended to be lower at days 0 and 7 in the FFP ( þ ) group (Figure 2) . These results indicated that the FFP infusions can suppress the increase in plasma VWF:AG in the early stages after SCT. Furthermore, in the FFP (À) group, high and/or intermediate molecular weight VWF multimers were lacking in the early stages and even in the later stage after SCT (Figure 3 ). In the FFP ( þ ) group, however, no apparent changes in VWF multimer patterns were found throughout SCT (Figure 3) . These results indicate that the supplementation of ADAMTS13 achieved by FFP administration may suppress the increase in VWF:AG that is extensively released from damaged endothelial cells after chemotherapy and/or total body irradiation. ADAMTS13 may be consumed to degrade a large amount of UL-VWFM released from damaged endothelial cells throughout SCT. We therefore were unable to observe any increase in ADAMTS13:AC supplemented by the administration of FFP in patients with FFP infusion. From this vantage point, FFP administration as a source of ADAMTS13 affords a compellingly effective means of preventing hepatic VOD.
In conclusion, hepatic VOD developed only in patients not receiving FFP infusions, probably because of increased VWF production relative to decreased ADAMTS13:AC throughout SCT, although other mechanisms may have played a role. Prophylactic FFP infusions should therefore be considered in patients at high risk of developing of hepatic VOD after SCT. 
